Big Pharma Challenges: Payer Environment Exacerbates Stagnant R&D Productivity

Today’s pharmaceutical industry faces unprecedented challenges. Our latest research report explores the key challenges facing pharma companies and includes case studies to provide context on the industry’s challenges.
 
 
Spread the Word
Listed Under

Tags:
* Big Pharma
* Patent Cliff
* Blockbuster

Industry:
* Biotech

Location:
* Kent Town - South Australia - Australia

Subject:
* Products

Sept. 5, 2012 - PRLog -- Wescadia Group, a life science consultancy firm, announces the release of its latest research report entitled “2012 – Big Pharma Challenges: An Overview and Case Studies on the Industry’s Headwinds”.

Today’s pharmaceutical industry faces unprecedented challenges. Among these broad challenges are the genericization of blockbuster brands, declining R&D productivity, and a challenging payer environment. Pharmaceutical companies have traditionally generated value through R&D. However, the decline in R&D productivity has forced companies to question the long-term sustainability of their own R&D. Our research shows that stagnant R&D productivity is a key cause of the problems faced by the industry, a view echoed by pharma executives. Evidence shows that the current output from R&D activities is insufficient to grow future sales. The purpose of this report is to explore the key challenges facing pharma companies and include case studies to provide context on the industry’s challenges.

Questions Answered:

•   What evidence is there to suggest that R&D productivity is a central cause of the challenges confronting pharma companies today?
•   How does a challenging payer environment exacerbate the R&D productivity issues facing pharma companies?
•   What factors will affect how much the “patent cliff” will impact on a company’s sales?
•   How has healthcare reform in the United States and austerity measures in Europe impacted on pharmaceutical sales for leading pharma companies?

Report Contents:

INTRODUCTION   
THE CHALLENGES   
PATENT EXPIRY OF BLOCKBUSTER BRANDS   
DECLINING R&D PRODUCTIVITY      
INCREASING COST TO DEVELOP PHARMACEUTICALS   
Morbidity and Mortality Evidence Potentially Increases Development Costs   
PAYER ENVIRONMENT      
Healthcare Reform in the United States      
Pricing Pressures in Europe Due to Austerity Measures      
Scrutiny from Payers on the Cost-Effectiveness of Pharmaceuticals   
R&D PRODUCTIVITY IS CENTRAL TO THE CHALLENGES FACING THE INDUSTRY   
CONCLUSION   

To order a copy of the report or for further information, please visit us at https://wescadiagroup.com/services/research/#recent.

About Wescadia Group

Wescadia Group is a healthcare consultancy firm that works with life science organizations to help them achieve sustainable growth, bring innovative treatments to market and maximize the value of their assets.    

Contact:

Wescadia Group Pty Ltd (ABN 26.156.459.504)
Marcus Bain
Managing Director
Phone: +61. 8.8125.5820
Email: marcus.bain@wescadiagroup.com
Website: http://wescadiagroup.com/
Facebook: http://www.facebook.com/pages/Wescadia-Group-Pty-Ltd/2824...
Linkedin: http://www.linkedin.com/company/2649650
Twitter: https://twitter.com/wescadiagroup
End
Source:
Email:***@wescadiagroup.com Email Verified
Phone:+61 487307214
Zip:5071
Tags:Big Pharma, Patent Cliff, Blockbuster
Industry:Biotech
Location:Kent Town - South Australia - Australia
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Wescadia Group Pty Ltd News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share